MK-677, L-692,429, and GHRP-6 Act as Neutral, Positive, or Negative Allosteric Modulators of Ghrelin Signaling at GHSR
Background
Growth hormone (GH) secretion is governed by the ghrelin receptor (GHSR1a), a GPCR whose endogenous ligand ghrelin stimulates the GH/IGF-1 axis. Multiple synthetic secretagogues — nonpeptide small molecules and peptide mimetics — have been developed to exploit this pathway clinically, yet their mechanistic relationship to endogenous ghrelin signaling has remained poorly characterized. Understanding whether these compounds simply mimic ghrelin or actively reshape its signaling has direct implications for drug design, since allosteric modulation at GHSR could amplify or suppress endogenous GH pulsatility in ways not captured by simple agonist models.
Study Design
Two nonpeptide agonists — MK-677 and L-692,429 — and two peptide agonists — GHRP-6 and ghrelin — were compared head-to-head in radioligand binding displacement assays and across five signal transduction readouts: calcium mobilization, inositol phosphate turnover, cAMP-responsive element (CRE)-controlled transcription, serum-responsive element (SRE)-controlled transcription, and arrestin mobilization. Coadministration experiments were also conducted to assess allosteric interactions between each synthetic agonist and ghrelin itself. No specific cell line, species, or n values are reported in the abstract.
Results
MK-677 behaved as a clean, simple agonist with a binding affinity of 6.5 nM and activated all five signaling systems with uniformly high potency (0.2–1.4 nM), consistent with full, balanced agonism across GHSR pathways. L-692,429 showed similarly uniform signaling potency (25–60 nM) across all assays, but its apparent binding affinity was ~1000-fold lower than its functional potency — a hallmark of allosteric engagement — and coadministration with ghrelin increased ghrelin's potency by 4- to 10-fold, identifying it as a positive allosteric modulator.
The maximal signaling efficacy for ghrelin was increased above that observed with ghrelin alone when co-administered with nonendogenous agonists, indicating super-additive ceiling effects not achievable by the endogenous hormone alone.
GHRP-6 showed the most heterogeneous profile: its potency varied 600-fold across assays (range 0.1–61 nM depending on pathway), and it acted as a negative allosteric modulator of ghrelin signaling. A receptor dimer model is proposed wherein ghrelin occupies one subunit and smaller synthetic ligands occupy the second subunit to exert co-agonism alongside neutral, positive, or negative modulation.
Key Findings
- MK-677 binding affinity: 6.5 nM; signaling potency 0.2–1.4 nM across all five assays — consistent simple agonism.
- L-692,429 apparent binding affinity ~1000-fold lower than its 25–60 nM functional signaling potency.
- L-692,429 increased ghrelin potency 4- to 10-fold, classifying it as a positive allosteric modulator.
- GHRP-6 potency varied 600-fold (0.1–61 nM) by assay and acted as a negative allosteric modulator of ghrelin.
- Co-administration of nonendogenous agonists raised ghrelin's maximal efficacy above the level achievable by ghrelin alone.
Why It Matters
The type of GHSR agonist chosen determines not just direct receptor activation but also how the body's own ghrelin pulses are amplified or suppressed. For clinicians and researchers, this means MK-677's pharmacological simplicity — balanced, high-potency agonism without allosteric interference — may explain part of its clean GH-secretion profile in humans. The finding that a positive allosteric modulator like L-692,429 can raise ghrelin's efficacy above its own ceiling suggests an optimal secretagogue drug would combine direct agonism with positive ghrelin modulation, potentially enabling lower doses with preserved or enhanced endogenous GH pulsatility. For stacking or protocol design, combining GHRP-6 with ghrelin or ghrelin analogues may be counterproductive due to negative modulation — a mechanistic caution not previously well-articulated.
TitrateLab articles covering MK-677
Written by TitrateLab, separately from the study summarized above.
